Results of a Phase III Trial that Explored Bevacizumab in Recurrent Cervical Cancer

June 10, 2013
Krishnansu S. Tewari, MD

Krishnansu S. Tewari, MD, describes a phase III trial conducted by the Gynecologic Oncology Group exploring treatment with bevacizumab for patients with recurrent cervical cancer.

Krishnansu S. Tewari, MD, a professor of obstetrics and gynecology at the University of California Irvine in Orange, California, describes a phase III trial conducted by the Gynecologic Oncology Group exploring treatment with bevacizumab for patients with recurrent cervical cancer.

Clinical Pearls

Patients with recurrent cervical cancer have few therapeutic options, Tewari notes. To help alleviate this, this trial compared a regimen of chemotherapy alone to chemotherapy plus bevacizumab and found an increase in overall survival of 3.7 months. Additionally, the side effect profile for the combination was consistent with expectations for bevacizumab as a monotherapy.

  • Patients with recurrent cervical cancer have few therapeutic options
  • A phase III trial performed by the GOG compared chemotherapy alone to chemotherapy plus bevacizumab
  • The median OS for patients who received the combination was 17.0 months compared 13.3 months
  • The side effect profile was consistent with bevacizumab monotherapy

<<<

View all coverage from the 2013 ASCO Meeting